Protocol Ledger

NCT05707377 · Phase II/III · ACTIVE NOT RECRUITING

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Interventional Phase II/III clinical trial protocol NCT05707377 sponsored by BeiGene in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-17 Enrollment: 178 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05707377
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)178 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05707377
Protocol FieldVerified Registry Value
NCT IdentifierNCT05707377
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment178 participants (ACTUAL)
Registered Start Date2023-04-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI